Anupam Rasayan India Limited — Investor Meet, 19-02-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Financial Performance: Anupam Rasayan India Ltd. posted consolidated operating revenue of INR 390 crore for Q3 FY '25, a significant 32% increase from INR 296 crore in Q3 FY '24, and a 33% rise from the prior quarter. Profit after tax grew impressively by 108% year-over-year to INR 54 crore. EBITDA for the quarter reached INR 121 crore, reflecting a 48% increase and resulting in margins of 31%, up 389 basis points. However, for the nine-month period, revenue decreased by 13% to INR 938 crore, with EBITDA declining 14% to INR 262 crore.

Future Outlook and Growth Drivers: Management expressed optimism, anticipating a revenue increase of 30% to 35% for FY '26, driven by recovery in agrochemical demand and sustained growth in the pharma and polymer segments. The launch of a 9.2 megawatt hybrid power plant is expected to enhance cost efficiencies. The strong pipeline in research and development, with over 65 molecules in various stages, positions the company for future growth.

Order Book and Operational Updates: The order book stands robust at approximately INR 10,700 crore, with INR 3,100 crore already commercialized. The company expects the majority of the remaining order book to be realized in FY '26.

Analyst Q&A Insights: Analysts questioned the decline in agrochem sales, attributed to a mix of customer-specific and market conditions, impacted by a withdrawal from a large customer which previously contributed 15% of revenue. Despite these setbacks, management is confident about recovering agrochemical demand moving forward. Analysts inquired about profitability and competitive positioning, with reassurance on margins due to operational efficiencies in pharma and polymer sectors.

Strategic Focus Areas: The management emphasized enhancing market diversification, particularly targeting growth from U.S. and Japanese markets, and leveraging emerging trends in fluorination chemistry.

Investor Insight: The strong rebound in revenue, backed by a positive outlook for multiple segments, combined with solid operational performance, suggest a favorable investment sentiment, aligning with a ‘buy’ stance given the growth potential.